We are live on ! Find out more

Smith & Nephew

SNN

Market cap $11.5B

27.50 USD

-0.12

0.43%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

27.50

0.00

0%

1 day

-0.43%

5 days

-4.41%

1 month

-8.36%

3 months

-10.34%

6 months

-17.57%

Year to date

-16.36%

1 year

-28.63%

5 years

-25.96%

10 years

-16.82%

About: Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.

Employees: 17,000

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 10%

Neutral 50%

Negative 40%

Smith & Nephew Plc Announces Cash Tender Offer for 2030 Bonds Up To $250m

Smith+Nephew announces cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 LONDON, UK / ACCESS Newswire / September 8, 2026 / Smith+Nephew, the global medical technology company (the "Company") (LSE:SN)(NYSE:SNN), announces today an offer to purchase for cash (the "Tender Offer"), upon the terms and subject to the conditions set forth in an offer to purchase dated September 8, 2026 (the "Offer to Purchase"), up to U.S.$250 million aggregate principal amount (the "Maximum Tender Amount") of the Company's 2.032% Senior Notes due 2030 (the "Notes") from each registered holder of the Notes (each a "Holder" and collectively, the "Holders"). Capitalized terms not otherwise defined in this announcement have the same meaning as assigned to them in the Offer to Purchase.

Smith & Nephew Plc Announces Cash Tender Offer for 2030 Bonds Up To $250m

Proactive Investors

Smith & Nephew keeps Jefferies 'buy' despite H2 growth scepticism

Smith & Nephew PLC (LSE:SN) drew a cautious assessment from Jefferies on Friday, with the broker maintaining its 'buy' rating despite investor scepticism over execution and a reduced financial year 2026 guidance. Shares in the company traded around 1,059p as Jefferies held its 1,500p price target, citing an all-time low valuation of 12 times estimated 2027 earnings alongside lumpy operational execution.

Smith & Nephew keeps Jefferies 'buy' despite H2 growth scepticism

Proactive Investors

Panmure Liberum cuts Smith & Nephew target price after disappointing results and CFO exit

Panmure Liberum has cut its target price for Smith & Nephew PLC (LSE:SN), the medical devices maker, to 1120p from 1250p, while maintaining its 'hold' rating. The broker said it still struggled to make a credible investment case after a disappointing second quarter and the departure of chief financial officer John Rogers, who is leaving to become CFO of Baxter.

Panmure Liberum cuts Smith & Nephew target price after disappointing results and CFO exit

Proactive Investors

UBS cuts Smith & Nephew target on competitive threats to three franchises

UBS has cut its price target on Smith & Nephew PLC (LSE:SN) to 1,120p from 1,300p, warning that even the medical device group's recently reduced guidance for this year remains at risk. The neutral rating is unchanged, with the new target implying about 3.5% upside from Monday's close of 1,082p.

UBS cuts Smith & Nephew target on competitive threats to three franchises

Zacks Investment Research

SNN Advances Surgical Robotics Through Imperial College Partnership

Smith+Nephew's five-year Imperial College London partnership targets less invasive robotic surgery and could speed research into clinical use.

SNN Advances Surgical Robotics Through Imperial College Partnership

Proactive Investors

Smith & Nephew shares slip on CFO's departure

Smith & Nephew PLC (LSE:SN) share prices weakened around 3% after the company announced that chief financial officer John Rogers will leave the company at the end of September. The medical technology group's shares fell as low as 3.5% in early London trading to around 1,072p against Tuesday's 1,110.5p close.

Smith & Nephew shares slip on CFO's departure

Proactive Investors

Smith & Nephew drops 3.5% as finance chief quits

Smith & Nephew PLC (LSE:SN) shares fell 3.5% to 1,071.84p early on Wednesday after finance chief John Rogers stepped down from the medical technology company's board with immediate effect. Rogers will officially leave his position as chief financial officer on 30 September as he takes up a new position in the US.

Smith & Nephew drops 3.5% as finance chief quits

Zacks Investment Research

Smith+Nephew Launches FLOW FLEXTEND COBLATION Wand for Hip Surgery

SNN launches the FLOW FLEXTEND COBLATION Wand, offering adjustable-angle access and precise tissue removal in complex joint procedures.

Smith+Nephew Launches FLOW FLEXTEND COBLATION Wand for Hip Surgery

Smith+Nephew and Imperial College London launch centre to accelerate innovation in surgical robotics

Smith+Nephew and Imperial College London have launched a five-year partnership to deliver research for robotic surgery for musculoskeletal conditions.

Smith+Nephew and Imperial College London launch centre to accelerate innovation in surgical robotics

Smith+Nephew's new FLOW FLEXTEND™ COBLATION™ Wand improves access¹* and resection efficiency²** for complex hip procedures vs. fixed-angle options

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces a breakthrough in RF resection technology for hip with its new FLOW FLEXTEND COBLATION Wand. Designed as an extension of its proprietary FLOW~IQ◊ technology with an adjustable-angle tip, the FLOW FLEXTEND Wand is designed to give surgeons enhanced joint access1 * and precise tissue targeting3 for hard-to-reach hip, knee and shoulder anatomies.

Smith+Nephew's new FLOW FLEXTEND™ COBLATION™ Wand improves access¹* and resection efficiency²** for complex hip procedures vs. fixed-angle options

See News Rankings

Price charts implemented using Lightweight Charts™